Movatterモバイル変換

[0]ホーム
URL:

SG156524A1 - New compounds useful for the treatment of obesity, type ii diabetes and cns disorders - Google Patents

New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Info

Publication number
SG156524A1
SG156524A1SG200604188-3ASG2006041883ASG156524A1SG 156524 A1SG156524 A1SG 156524A1SG 2006041883 ASG2006041883 ASG 2006041883ASG 156524 A1SG156524 A1SG 156524A1
Authority
SG
Singapore
Prior art keywords
obesity
diabetes
treatment
type
cns disorders
Prior art date
Application number
SG200604188-3A
Inventor
Gary Johansson
Annika Jenmalm-Jensen
Katarina Beierlein
Original Assignee
Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201925Aexternal-prioritypatent/SE0201925D0/en
Priority claimed from SE0202181Aexternal-prioritypatent/SE0202181D0/en
Priority claimed from SE0202908Aexternal-prioritypatent/SE0202908D0/en
Priority claimed from SE0300357Aexternal-prioritypatent/SE0300357D0/en
Application filed by Biovitrum Ab PublfiledCriticalBiovitrum Ab Publ
Publication of SG156524A1publicationCriticalpatent/SG156524A1/en

Links

Classifications

Landscapes

Abstract

The present invention relates to compounds of the general formula (I), wherein P is sulfone or sulfonamide; and A, B, W, X, Y and R3 are defined in the description; to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and/or CNS disorders, to achieve reduction of body weight and of body weight gain.
SG200604188-3A2002-06-202003-06-19New compounds useful for the treatment of obesity, type ii diabetes and cns disordersSG156524A1 (en)

Applications Claiming Priority (7)

Application NumberPriority DateFiling DateTitle
SE0201925ASE0201925D0 (en)2002-06-202002-06-20 New compounds
SE0202181ASE0202181D0 (en)2002-07-112002-07-11 New compounds
US40612002P2002-08-262002-08-26
SE0202908ASE0202908D0 (en)2002-10-012002-10-01 New compounds
US43401002P2002-12-172002-12-17
SE0300357ASE0300357D0 (en)2003-02-102003-02-10 New compounds
US46470103P2003-04-232003-04-23

Publications (1)

Publication NumberPublication Date
SG156524A1true SG156524A1 (en)2009-11-26

Family

ID=30004107

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG200604188-3ASG156524A1 (en)2002-06-202003-06-19New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Country Status (13)

CountryLink
EP (1)EP1513828A1 (en)
CN (1)CN1662521A (en)
AU (1)AU2003243091A1 (en)
BR (1)BR0311952A (en)
CA (1)CA2486989A1 (en)
EA (2)EA011581B1 (en)
IL (1)IL165051A0 (en)
MX (1)MXPA04012914A (en)
NO (1)NO20050294L (en)
NZ (3)NZ552282A (en)
RS (1)RS111204A (en)
SG (1)SG156524A1 (en)
WO (1)WO2004000828A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
NZ535239A (en)2002-03-272008-03-28Glaxo Group LtdQuinoline derivatives and their use as 5-HT6 ligands
SE0301446D0 (en)*2003-05-162003-05-16Astrazeneca Ab New Compounds
TWI328009B (en)2003-05-212010-08-01Glaxo Group LtdQuinoline derivatives as phosphodiesterase inhibitors
WO2005012254A1 (en)2003-07-222005-02-10Arena Pharmaceuticals, Inc.Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto
SE0302760D0 (en)*2003-10-202003-10-20Biovitrum Ab New compounds
SE0303480D0 (en)2003-12-192003-12-19Biovitrum Ab Benzofuranes
AU2004299438A1 (en)*2003-12-192005-06-30Biovitrum AbNovel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-HT6 receptor-related disorder
GB0407025D0 (en)*2004-03-292004-04-28Glaxo Group LtdNovel compounds
TWI380816B (en)*2004-04-132013-01-01Synta Pharmaceuticals CorpDisalt inhibitors of il-12 production
WO2006062481A1 (en)*2004-12-092006-06-15Biovitrum AbNew benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
AR054044A1 (en)*2005-05-232007-05-30Astrazeneca Ab CHROMAN AND TETRAHYDRONAFTALENE DERIVATIVES AS RECEPTOR MODULATORS 5 - HT6; INTERMEDIARIES IN THEIR PREPARATION; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPELO IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CNS AND OBESITY DISEASES.
US7582767B2 (en)*2005-06-172009-09-01Biovitrum Ab (Publ.)Substituted sulphonamide compound and uses thereof
WO2007003961A2 (en)*2005-06-302007-01-11Prosidion LimitedGpcr agonists
EA024305B1 (en)2005-10-072016-09-30Экселиксис, Инк.Phosphatidylinositol 3-kinase inhibitors and use thereof
EP2027104B1 (en)2005-11-032011-02-23F. Hoffmann-La Roche AGArylsulfonylchromans as 5-ht6 inhibitors
TW200736227A (en)2005-12-232007-10-01Astrazeneca AbNew compounds III
AU2007263084A1 (en)2006-06-202007-12-27F. Hoffmann-La Roche AgTetralin and indane derivatives and uses thereof
KR101064001B1 (en)2006-06-202011-09-08에프. 호프만-라 로슈 아게 Arylsulfonamidyl tetralin derivatives and uses thereof
BRPI0713742A2 (en)2006-06-202013-02-13Hoffmann La Roche arylsulfonyl naphthalene derivatives and uses of these
TWI433839B (en)2006-08-112014-04-11Neomed Inst Novel benzimidazole derivatives 290
EP2254564A1 (en)2007-12-122010-12-01Glaxo Group LimitedCombinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en)2008-04-022009-10-08Arena Pharmaceuticals, Inc.Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US7888662B2 (en)2008-06-202011-02-15Varian Semiconductor Equipment Associates, Inc.Ion source cleaning method and apparatus
US9126946B2 (en)2008-10-282015-09-08Arena Pharmaceuticals, Inc.Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
KR20140038443A (en)*2011-05-092014-03-28포르마 티엠, 엘엘씨.Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
WO2015090233A1 (en)2013-12-202015-06-25Sunshine Lake Pharma Co., Ltd.Aromatic heterocyclic compounds and their application in pharmaceuticals
JP2018516992A (en)2015-06-122018-06-28アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ Diaryl and arylheteroaryl urea derivatives useful for the prevention and treatment of REM sleep behavior disorder
CA2992518A1 (en)2015-07-152017-01-19Axovant Sciences GmbhDiaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2017147328A1 (en)2016-02-232017-08-31Portola Pharmaceuticals, Inc.Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Citations (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO1998027081A1 (en)*1996-12-191998-06-25Smithkline Beecham PlcSulphonamide derivatives, process for their preparation, and their use as medicaments
WO2001032646A2 (en)*1999-11-052001-05-10Smithkline Beecham P.L.C.Sulfonamide derivatives
WO2001032660A1 (en)*1999-11-052001-05-10Nps Allelix Corp.Compounds having 5-ht6 receptor antagonist activity
WO2002032863A1 (en)*2000-10-202002-04-25Biovitrum Ab2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
WO2002098857A1 (en)*2001-06-072002-12-12F. Hoffmann-La Roche AgNew indole derivatives with 5-ht6 receptor affinity
WO2002100822A1 (en)*2001-06-112002-12-19Biovitrum AbSubstituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
GB947606A (en)*1961-04-101964-01-22Ici LtdN-substituted piperazines
US4808595A (en)*1986-12-241989-02-28Merck & Co., Inc.Furopyridine sulfonamides and their opthalmological compositions
CA2158457C (en)*1993-03-162001-04-17Bertrand Leo ChenardNaphthalene derivatives
US5597826A (en)*1994-09-141997-01-28Pfizer Inc.Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
GB9818916D0 (en)*1998-08-281998-10-21Smithkline Beecham PlcUse
GB9904995D0 (en)*1999-03-041999-04-28Glaxo Group LtdSubstituted aza-oxindole derivatives
CA2408156A1 (en)*2000-05-052001-11-15Millennium Pharmaceuticals, Inc.Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
AU2001259707A1 (en)*2000-06-142001-12-24Warner Lambert Company6,5-fused bicyclic heterocycles
CN1329382C (en)*2001-05-112007-08-01比奥维特罗姆股份公司Novel arylsusfonamide compounds for treatment of obesity, type II diabetes and CNS-disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO1998027081A1 (en)*1996-12-191998-06-25Smithkline Beecham PlcSulphonamide derivatives, process for their preparation, and their use as medicaments
WO2001032646A2 (en)*1999-11-052001-05-10Smithkline Beecham P.L.C.Sulfonamide derivatives
WO2001032660A1 (en)*1999-11-052001-05-10Nps Allelix Corp.Compounds having 5-ht6 receptor antagonist activity
WO2002032863A1 (en)*2000-10-202002-04-25Biovitrum Ab2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
WO2002098857A1 (en)*2001-06-072002-12-12F. Hoffmann-La Roche AgNew indole derivatives with 5-ht6 receptor affinity
WO2002100822A1 (en)*2001-06-112002-12-19Biovitrum AbSubstituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
METHVIN ISAAC ET AL.: '6-Bicyclopiperazinyl-1-arylsulfonylindoles and 6-bicyclopiperidinyl-1-arylsulfonylindoles derivatives as novel, potent and selective 5-HT6 receptor antagonists' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS vol. 10, no. 15, 2000, pages 1719 - 1721*

Also Published As

Publication numberPublication date
WO2004000828A1 (en)2003-12-31
CA2486989A1 (en)2003-12-31
EA200500054A1 (en)2005-06-30
BR0311952A (en)2005-04-19
RS111204A (en)2006-12-15
EA011581B1 (en)2009-04-28
IL165051A0 (en)2005-12-18
CN1662521A (en)2005-08-31
EA200600975A1 (en)2006-10-27
NO20050294L (en)2005-02-04
MXPA04012914A (en)2005-03-31
EP1513828A1 (en)2005-03-16
NZ552283A (en)2008-07-31
NZ536600A (en)2007-08-31
EA008835B1 (en)2007-08-31
NZ552282A (en)2008-07-31
AU2003243091A1 (en)2004-01-06

Similar Documents

PublicationPublication DateTitle
SG156524A1 (en)New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
YU98003A (en)Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
EP1562897A4 (en)Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
DE602004011394D1 (en)Thiazolderivate
AP2088A (en)Phenethanolamine derivatives for treatment of respiratory diseases
GB0225475D0 (en)Therapeutic agents
MXPA04002405A (en)Phenethanolamine derivatives for treatment of respiratory diseases.
AU2804400A (en)Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
WO2004037768A3 (en)Phenethanolamine derivatives
WO2001081310A8 (en)1-aroyl-piperidinyl benzamidines
IL171977A (en)Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
ATE381537T1 (en) FORMANILIDE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS
PL369108A1 (en)17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA04005886A (en)Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands.
RS65704A (en)Aza-arylpiperazines
UA83233C2 (en)Substituted 2-aminotetralin for the treatment of depression
GB0102672D0 (en)Compounds
SE0202429D0 (en) Novel Compounds
MD2447F2 (en)Pharmaceutical composition, use thereof and methods of treatment of cephalalgia, migraine, sickness and vomiting
MY143390A (en)Sulfonamide derivatives for the treatment of diseases.
IL184116A0 (en)Use of thiazolidinone derivatives as antiangiogenic agents
DE60233350D1 (en) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
NO20052699L (en) 4 (phenylpiperazinylmethyl) benzamide derivatives and their use in the treatment of pain and gastrointestinal disorders.
WO2005110413A3 (en)Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
WO2004037166A3 (en)Therapeutic guanidines
[8]ページ先頭
©2009-2025 Movatter.jp